J Liver Cancer Search

CLOSE


Peer review policy

  • HOME
  • EDITORIAL POLICY
  • Peer review policy

The acceptance criteria for all papers are the quality and originality of the research and its significance to the journal readership. All manuscripts, including solicited manuscripts, are screened upon submission to Journal of Liver Cancer (JLC). Only those which fully comply with the submission requirements outlined, including ethics statements, and in which the level of English is of an acceptable standard will enter the peer review process. The Editors reserve the right of early rejection without further external review if the manuscript is judged unlikely to be accepted.

Before reviewing, all submitted manuscripts are inspected by Similarity Check powered by iThenticate
(https://www.crossref.org/services/similarity-check/), a plagiarism-screening tool. If the similarity score is too high, the Editorial Board will do a more profound content screening. The criterion for similarity rate for further screening is usually 15%; however, the excess amount of similarity in specific sentences may be also checked in every manuscript. The settings for Similarity Check screening are as follows: It excludes quotes, bibliography, small matches of 6 words, small sources of 1%, and the Methods section.

JLC adopts a single-blind peer review process: the reviewers know the identity of the authors, but not vice versa. Manuscripts will be evaluated by at least 2 independent reviewers and by the Editors.

The role of the reviewers is to advise editors to revise, accept, or reject an individual manuscript. Judgments should be objective and comments should be lucidly described. Scientific soundness is the most important value of the journal; therefore, logic and statistical analysis should be considered meticulously. The use of reporting guideline is recommended for review. Reviewers should have no conflicts of interest. Reviewers should point out relevant published work which is not yet cited. Reviewed articles are managed confidentially. After review, the Editorial Board determines whether the manuscript is accepted for publication or not.

The Editor-in-Chief is responsible for the final decision for the manuscript. The final decision letter is sent to the corresponding author by e-mail within approximately 6 weeks after submission. All articles are published ahead-of-print within 2 months after final acceptance by the Editorial Office, and the final print version published within 6 months after final acceptance.

The authors may be requested to revise the contents. Revised manuscripts are peer reviewed in the same manner as for the initial submission. This invitation does not imply, in any case, that the revised version will be accepted for publication. Authors should submit both a marked and unmarked version of the revised manuscript, with all changes in the marked copy underlined. The resubmitted manuscript should be accompanied by a cover letter stating that the manuscript has been revised according to the comments made by the Editor and the Reviewers. Figures and tables must be uploaded in the recommended formats. Revised manuscripts should be accompanied by a point-by-point reply to the critiques, specifying the changes made in the revised version, which should be highlighted. Failure to resubmit the revised manuscript within 4 weeks of the editorial decision is regarded as a withdrawal. Once rejected, the manuscript does not undergo another round of review.

If manuscripts from the Editor-in-Chief, the Deputy/Associate Editors or the Editorial Board are submitted, they also undergo the same process as with other manuscripts. Editors will not handle their own manuscripts and are not involved in the peer reviewer selection, review process, or final decision.



  • KoreaMed
  • KoMCI
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR AUTHORS AND REVIEWERS
Editorial Office
1521 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2021 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next